This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Summary statistics from individual studies were used.
Number of primary studies included
At least 17 primary studies were included in the review.
Methods of combining primary studies
The narrative method was used to combine studies.
Investigation of differences between primary studies
Results of the review
The initial mean CD4 cell count ranged from 217 to 377 per cubic millimetre. The rate of HIV RNA suppression was 44% at 24 weeks. The rate of viral suppression at 52 weeks was 53% in the three-drug group. The rate of viral suppression at 48 weeks ranged from 48% to 70%. The mean monthly decline in the CD4 cell count ranged from 6.375 to 3.025 cells per cubic millimetre.
The probability of pneumocystis carinii pneumonia (PCP) ranged from 0.037 to 0.00041. The probability of mycobacterium avium complex (MAC) ranged from 0.0122 to 0.000059. The probability of toxoplasmosis ranged from 0.0027 to 0.000029. The probability of cytomegalovirus ranged from 0.01857 to 0.000059. The probability of fungal infection ranged from 0.01123 to 0.000088. The probability of other infections ranged from 0.003940 to 0.000470.
The efficacy of prophylaxis against PCP and MAC infections was 97.32% and 63.35%, respectively. Immunologic efficacy of regenerated CD4 cells was similar to that of the cells that predated the HIV-associated decline in the CD4 cell count. Antiretroviral therapy ceased to confer benefits after two years.
Measure of benefits used in the economic analysis
Life years and quality-adjusted life years (QALYs) were used as the measures of benefit. Quality of life estimates were derived from a questionnaire item about overall health status used in several AIDS Clinical Trials Group studies. Patients' responses were converted to quality of life scores by the method of Torrance. Benefits were discounted at an annual rate of 3%.
Direct costs
Direct costs were discounted at an annual rate of 3% (time horizon greater than one year). Quantities and costs were reported separately. Direct costs included costs of treatment for acute illnesses and of routine medical care, costs for CD4 cell counts and HIV RNA tests, and drug costs. The quantity/cost boundary adopted was that of the health service. The estimation of quantities and costs was based on actual data. Costs and quantities were obtained from the AIDS Cost and Services Utilization Survey, the Payment Office at Boston Medical Center, and the Red Book. Charges were converted into costs using a national cost-to-charge ratio. Costs were converted to 1998 values using the medical-care
The estimation of benefits was obtained directly from the effectiveness analysis. Estimation of QALYs was modelled. The instrument used to derive benefits, the method of Torrance, was appropriate. By including QALYs as one of their benefit measures, the authors have enhanced the comparability of the intervention with respect to those in other clinical domains.
Validity of estimate of costs
Good features of the cost analysis were that all relevant direct cost categories were included, quantities and costs were reported separately, the price year was reported, and charges were converted to costs. The validity of the cost results was further enhanced by appropriate sensitivity analyses over reasonable ranges. The authors did not include indirect costs, such as lost wages arising from time spent obtaining care, which would be relevant if the perspective of interest was that of society.
Other issues
This was a methodologically sound and comprehensive economic evaluation using modelling techniques. The authors did make appropriate comparisons of their findings with those from other studies and the issue of generalisability to other settings was addressed. The authors did not present their results selectively. The study considered HIV-infected patients and this was reflected in the authors' conclusions.
Implications of the study
The authors' findings suggest that three-drug antiretroviral therapy is highly cost-effective and should be made available to all patients who can benefit from it. As the intervention was both more costly and more effective, however, this statement should be viewed within the context of a decision-maker's willingness to pay threshold. Better data on the long-term effects and toxicity of combination antiretroviral therapy, the costs of routine care with current regimens, and the effects of interventions designed to improve adherence to the regimens and decrease the rate of treatment failure, are needed.
